Diarrhea News and Research

Latest Diarrhea News and Research

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Onconova Therapeutics, Inc. announced two advances in the clinical development of ESTYBON (rigosertib, ON 01910.Na) in presentations at the annual meeting of the American Society of Clinical Oncology (ASCO), June 3-7, 2011, in Chicago, Illinois.

6 Jun 2011

Several drug makers plan to lower prices of vaccines for GAVI purchase

Several pharmaceutical companies have pledged to lower the prices of vaccines against childhood illnesses ahead of the GAVI Alliance conference in London next week, the Guardian reports (Quinn, 6/6).

6 Jun 2011

United Therapeutics completes oral treprostinil Phase 3 trial on pulmonary arterial hypertension

United Therapeutics Corporation announced today the completion of its FREEDOM-M Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension (PAH).

6 Jun 2011

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Genentech, a member of the Roche Group, today announced results from OCEANS, a Phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.

6 Jun 2011

Synta presents ganetespib Phase 2 trial results in advanced non-small cell lung cancer at ASCO 2011

Synta Pharmaceuticals Corp. today presented results at the Annual Meeting of the American Society for Clinical Oncology (ASCO) from a Phase 2 single agent clinical trial of ganetespib in advanced non-small cell lung cancer (NSCLC) that showed promising clinical activity in patients with progressive disease.

6 Jun 2011

Bayer's radium-223 chloride Phase III trial in CRPC, bone metastases meet primary endpoint

Bayer HealthCare Pharmaceuticals Inc. today announced that the Phase III ALSYMPCA trial evaluating Bayer's investigational compound, radium-223 chloride, which is exclusively licensed from Algeta ASA, in patients with castration-resistant prostate cancer (CRPC) and bone metastases met its primary endpoint by significantly improving overall survival.

6 Jun 2011

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Incyte Corporation announced today results from the global, pivotal Phase III clinical program of ruxolitinib in patients with myelofibrosis (MF) at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting.

6 Jun 2011

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb Company today announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY (ipilimumab) prolonged the lives of patients with metastatic melanoma.

6 Jun 2011

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

6 Jun 2011

Bharat Biotech announces the pricing for ROTAVAC vaccine

Bharat Biotech today announced the price of ROTAVAC India’s first indigenously developed Rotavirus Vaccine. The vaccine will be sold to global public markets, Governments worldwide including UN procurement agencies at a price of US $ 1.0. Bharat Biotech hopes its new vaccine will help prevent part of the ~ 500,000 child deaths each year caused due to rotavirus diarrhea and improve access to better, affordable rotavirus vaccines.

6 Jun 2011

New E. coli outbreak alarms Europe

An Escherichia coli (E. coli) outbreak of disease in Germany has left 22 people dead and it is alarming populations across Europe.

5 Jun 2011

Preliminary data from Ion PGM sequencer reveals German E. coli outbreak is a new hybrid strain

Life Technologies Corporation today announced that preliminary data from DNA sequencing performed in cooperation with the University Hospital Muenster, Germany, on the Ion Personal Genome Machine strongly suggests that the bacterium at the root of the deadly outbreak in Germany is a new hybrid type of pathogenic E. coli strains.

4 Jun 2011

BGI genome sequencing identifies new super-toxic bacteria as cause of current European epidemic

The recent outbreak of an E. coli infection in Germany has resulted in serious concerns about the potential appearance of a new deadly strain of bacteria.

4 Jun 2011

Genentech, Astellas announce results of Tarceva Phase III study against advanced NSCLC

Genentech, a member of the Roche Group and Astellas Pharma US, Inc., today announced results of EURTAC, the first Phase III study with Tarceva in Western patients with a genetically distinct type of advanced non-small cell lung cancer (NSCLC).

4 Jun 2011

American College of Gastroenterology offers resources on foodborne illness, tips for food safety

For consumers in the United States concerned by the outbreak of E. coli in Europe, the American College of Gastroenterology offers background on foodborne illness, tips for food safety, and expert insight from its resources on digestive health on what to do in the case of foodborne illness.

4 Jun 2011

New approach for treatment of infections of urinary tract

One in three women will be faced at least once in her life with cystitis, for some the start of a constantly recurring infection. Cystitis is caused by Escherichia coli bacteria which fasten on to the wall of the bladder by means of thread-like structures (pili).

4 Jun 2011

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Bristol-Myers Squibb Company announced today it has entered in to a clinical collaboration agreement with Roche to evaluate the utility of Bristol-Myers Squibb's CTLA-4 inhibitor, YERVOY (ipilimumab), in combination with Roche's investigational oral BRAF inhibitor, vemurafenib, in treating patients with a specific type of metastatic melanoma.

4 Jun 2011

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

Data related to ZYTIGA (abiraterone acetate) will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

3 Jun 2011

Majority of patients with ulcerative colitis eager to undergo fecal microbiota transplantation

The first study of the social and ethical issues associated with a provocative approach to treatment for ulcerative colitis has found that the majority of potential patients are eager for what is now called "fecal microbiota transplantation" to become available, although many have concerns about donor selection, screening, and methods of delivery.

3 Jun 2011

Mass vaccination strategy could prevent future cholera epidemics in Zimbabwe

Mathematical models analyzing how a cholera outbreak spread in Zimbabwe are providing new insights into the most effective vaccination strategies for preventing future cholera epidemics, according to University of Florida researchers.

3 Jun 2011

Diarrhea News and Research

Latest Diarrhea News and Research

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Several drug makers plan to lower prices of vaccines for GAVI purchase

United Therapeutics completes oral treprostinil Phase 3 trial on pulmonary arterial hypertension

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Synta presents ganetespib Phase 2 trial results in advanced non-small cell lung cancer at ASCO 2011

Bayer's radium-223 chloride Phase III trial in CRPC, bone metastases meet primary endpoint

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Bharat Biotech announces the pricing for ROTAVAC vaccine

New E. coli outbreak alarms Europe

Preliminary data from Ion PGM sequencer reveals German E. coli outbreak is a new hybrid strain

BGI genome sequencing identifies new super-toxic bacteria as cause of current European epidemic

Genentech, Astellas announce results of Tarceva Phase III study against advanced NSCLC

American College of Gastroenterology offers resources on foodborne illness, tips for food safety

New approach for treatment of infections of urinary tract

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

Majority of patients with ulcerative colitis eager to undergo fecal microbiota transplantation

Mass vaccination strategy could prevent future cholera epidemics in Zimbabwe

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Diarrhea News and Research

Latest Diarrhea News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in